# Cencora, Inc.: Form 10-Q for the period ended Mar 31, 2017

- Company: [Cencora, Inc.](/companies/cor.md) (CIK 1140859)
- Form: 10-Q
- Filed: 2017-05-04
- Accepted by EDGAR: May 4, 2017, 18:34 ET
- Period: 2017-03-31
- Accession: 0001140859-17-000020
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1140859/000114085917000020/abc10-qx3312017.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1140859/000114085917000020/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2017-03-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2017-01-01 to 2017-03-31 | $37.15bn | us-gaap:Revenues |
| Revenue | 6 months, 2016-10-01 to 2017-03-31 | $75.32bn | us-gaap:Revenues |
| Cost of revenue | 3 months, 2017-01-01 to 2017-03-31 | $35.89bn | us-gaap:CostOfGoodsSold |
| Cost of revenue | 6 months, 2016-10-01 to 2017-03-31 | $73.02bn | us-gaap:CostOfGoodsSold |
| Gross profit | 3 months, 2017-01-01 to 2017-03-31 | $1.26bn | us-gaap:GrossProfit |
| Gross profit | 6 months, 2016-10-01 to 2017-03-31 | $2.29bn | us-gaap:GrossProfit |
| Selling, general and administrative | 3 months, 2017-01-01 to 2017-03-31 | $521.8m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 6 months, 2016-10-01 to 2017-03-31 | $1.04bn | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months, 2017-01-01 to 2017-03-31 | $625.0m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months, 2016-10-01 to 2017-03-31 | $1.02bn | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months, 2017-01-01 to 2017-03-31 | $181.4m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months, 2016-10-01 to 2017-03-31 | $297.3m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2017-01-01 to 2017-03-31 | $411.5m | us-gaap:NetIncomeLoss |
| Net income | 6 months, 2016-10-01 to 2017-03-31 | $658.7m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2017-01-01 to 2017-03-31 | $1.86 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months, 2016-10-01 to 2017-03-31 | $2.97 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2017-01-01 to 2017-03-31 | $1.89 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months, 2016-10-01 to 2017-03-31 | $3.02 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2017-01-01 to 2017-03-31 | 221,221,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months, 2016-10-01 to 2017-03-31 | 221,611,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months, 2016-10-01 to 2017-03-31 | $368.4m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months, 2016-10-01 to 2017-03-31 | $262.7m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Dividends paid | 6 months, 2016-10-01 to 2017-03-31 | $160.1m | us-gaap:PaymentsOfDividendsCommonStock |
| Share repurchases | 6 months, 2016-10-01 to 2017-03-31 | $229.9m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | at 2017-03-31 | $2.40bn | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2017-03-31 | $23.49bn | us-gaap:AssetsCurrent |
| Total assets | at 2017-03-31 | $34.40bn | us-gaap:Assets |
| Current liabilities | at 2017-03-31 | $25.53bn | us-gaap:LiabilitiesCurrent |
| Long-term debt | at 2017-03-31 | $3.48bn | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | at 2017-03-31 | $615.8m | us-gaap:LongTermDebtCurrent |
| Shareholders' equity | at 2017-03-31 | $2.53bn | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 51,709 characters.

### Overview

The following discussion should be read in conjunction with the Consolidated Financial Statements and notes thereto contained herein and in conjunction with the financial statements and related notes included in our Annual Report on Form 10-K for the fiscal year ended September 30, 2016.

We are one of the largest global pharmaceutical sourcing and distribution services companies, helping both healthcare providers and pharmaceutical and biotech manufacturers improve patient access to products and enhance patient care. We deliver innovative programs and services designed to increase the effectiveness and efficiency of the pharmaceutical supply chain in both human and animal health. We are organized based upon the products and services we provide to our customers. Our operations are comprised of the Pharmaceutical Distribution Services reportable segment and Other.

### Pharmaceutical Distribution Services Segment

The Pharmaceutical Distribution Services reportable segment is comprised of two operating segments, which include the operations of AmerisourceBergen Drug Corporation ("ABDC") and AmerisourceBergen Specialty Group ("ABSG"). Servicing healthcare providers in the pharmaceutical supply channel, the Pharmaceutical Distribution Services segment's operations provide drug distribution and related services designed to reduce healthcare costs and improve patient outcomes.

ABDC distributes a comprehensive offering of brand-name and generic pharmaceuticals (including specialty pharmaceutical products), over-the-counter healthcare products, home healthcare supplies and equipment, outsourced compounded sterile preparations, and related services to a wide variety of healthcare providers, including acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers. ABDC also provides pharmacy management, staffing and additional consulting services, and supply management software to a variety of retail and institutional healthcare providers. Additionally, ABDC delivers packaging solutions to institutional and retail healthcare providers.

ABSG, through a number of operating businesses, provides pharmaceutical distribution and additional services to physicians who specialize in a variety of disease states, especially oncology, and to other healthcare providers, including hospitals and dialysis clinics. ABSG also distributes plasma and other blood products, injectible pharmaceuticals, vaccines, and other specialty products. Additionally, ABSG provides third party logistics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers.

Our use of the term "specialty" and "specialty pharmaceutical products" refers to drugs used to treat complex diseases, such as cancer, diabetes, and multiple sclerosis. Specialty pharmaceutical products are part of complex treatment regimens for serious conditions and diseases that generally require ongoing clinical monitoring. We believe the terms "specialty" and "specialty pharmaceutical products" are used consistently by industry participants and our competitors. However, we cannot be certain that other distributors of specialty products define these and other similar terms in exactly the same manner as we do.

Both ABDC and ABSG distribute specialty drugs to their customers, with the principal difference between these two operating segments being that ABSG operates distribution facilities that focus primarily on complex disease treatment regimens. Therefore, a product distributed from one of ABSG's distribution facilities results in revenue reported under ABSG, and a product distributed from one of ABDC's distribution centers results in revenue reported under ABDC. Essentially all of ABSG's sales consist of specialty pharmaceutical products.

### Other

Other consists of operating segments that focus on manufacturer and other services and includes AmerisourceBergen Consulting Services ("ABCS"), World Courier, and MWI Animal Health ("MWI"). The results of operations of these operating segments are not significant enough to require separate reportable segment disclosure, and therefore, have been included in "Other" for the purpose of our reportable segment presentation.

ABCS, through a number of operating businesses, provides a full suite of integrated manufacturer services that range from clinical trial support to product post-approval and commercialization support. World Courier, which operates in over 50 countries, is a leading global specialty transportation and logistics provider for the biopharmaceutical industry. MWI is a leading animal health distribution company in the United States and in the United Kingdom. MWI sells pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and various other products to customers in both the companion animal and production animal markets. Additionally, MWI offers demand-creating sales force services to manufacturers.

### Recent Development

Our contract with Express Scripts was scheduled to expire in September 2017. In April 2017, we signed a new five-year agreement with Express Scripts that expires in September 2022. The fiscal 2016 revenue from our current agreement with Express Scripts was approximately $23 billion.

### Executive Summary

This executive summary provides highlights from the results of operations that follow:

- Revenue increased 4.1% and 4.0% from the prior year quarter and six month period, respectively, as a result of increased sales to some of ABDC's larger customers and the strong revenue growth of certain business units within ABSG;
- Pharmaceutical Distribution Services gross profit decreased 1.5% and 1.8% from the prior year quarter and six month period, respectively. Gross profit in the current year quarter was adversely impacted by prior year contract renewals in the second half of fiscal 2016 at less favorable terms with a significant group purchasing organization ("GPO") customer and Kaiser Permanente ("Kaiser") and a lower contribution from PharMEDium as it shipped fewer units while we increased our investment in quality control and quality assurance systems to enhance product quality and patient safety and to meet all of PharMEDium's commitments to the U.S. Food and Drug Administration ("FDA") pursuant to the new federal requirements for outsourcing facilities. Gross profit growth in the current year six month period was adversely impacted by the above-mentioned contract renewals and lower price appreciation, offset in part by the incremental contribution from PharMEDium, which was acquired on November 6, 2015;
- Total gross profit increased 16.8% in the current year quarter primarily due to the reduction of last-in, first-out ("LIFO") expense, which was a credit of $86.5 million in the current year quarter, in comparison to an expense charge of $92.4 million in the prior year quarter. Total gross profit increased 12.4% in the current year six month period primarily due to the reduction of LIFO expense, which was a credit of $58.2 million in the current year six month period, in comparison to an expense charge of $193.9 million in the prior year six month period. The LIFO credit in the current year quarter and six month period was primarily driven by lower expected brand inflation and greater generic deflation for fiscal 2017 in comparison to those expectations at March 31, 2016 for the prior fiscal year;
- Distribution, selling, and administrative expenses were relatively flat compared to the prior year quarter and six month period. Distribution, selling, and administrative expenses as a percentage of revenue were 1.40% and 1.38% in the current year quarter and six month period, respectively, and represent a decrease of 6 basis points compared to the prior year periods. The decreases in expense as a percentage of revenue in comparison to the prior year periods were primarily due to initiatives taken in second half of fiscal 2016 to improve operating efficiency across many of our businesses and certain administrative functions;
- Total operating expenses increased $506.6 million from the prior year quarter, which included Warrants income of $503.9 million. There was no comparable income in the current year quarter;
- Total segment operating income decreased by 1.0% compared to the prior year quarter primarily due to the decline in ABDC's operating income due to the gross profit factors noted above and was partially offset by increased contributions from ABSG and our businesses in Other. Total segment operating income increased by 0.3% compared to the prior year six month period due to increased contributions from ABSG and our businesses in Other and was partially offset by the decline in ABDC's operating income due to the gross profit factors noted above, and;
- Our effective tax rates were 30.6% and 31.1% in the three and six months ended March 31, 2017, respectively. Our effective tax rates were 34.1% and (32.6)% in the three and six months ended March 31, 2016, respectively. Our effective tax rates in the three and six months ended March 31, 2017 were favorably impacted due to growth of our international businesses and also benefited from stock option exercises and restricted stock vesting. Prior to fiscal 2017, tax benefits resulting from share-based compensation were recorded as adjustments to Additional Paid-In Capital within Stockholders' Equity (see Note 1 of the Notes to Consolidated Financial Statements). Our effective tax rate in the six months ended March 31, 2016 benefited from the receipt of an Internal Revenue Service ("IRS") private letter ruling that entitled us to an income tax deduction equal to the fair value of the Warrants on the dates of exercise.

### Results of Operations

### Revenue

*(dollars in thousands)*

|  | Three months ended March 31, 2017 | 2016 | Change | Six months ended March 31, 2017 | 2016 | Change |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Pharmaceutical Distribution Services | $35,518,955 | $34,165,733 | 4.0% | $72,094,922 | $69,360,412 | 3.9% |
| Other | 1,696,137 | 1,599,805 | 6.0% | 3,359,791 | 3,177,620 | 5.7% |
| Intersegment eliminations | (67,690) | (67,181) | 0.8% | (138,046) | (130,629) | 5.7% |
| Revenue | $37,147,402 | $35,698,357 | 4.1% | $75,316,667 | $72,407,403 | 4.0% |

Revenue increased by 4.1% and 4.0% from the prior year quarter and six month period, respectively. See discussions below under "Pharmaceutical Distribution Services Segment" and "Other" for commentary regarding our revenue growth.

We currently expect our revenue in fiscal 2017 to increase between 5.5% and 6.5%. Our future revenue growth will continue to be affected by various factors such as industry growth trends, including drug utilization, the introduction of new innovative brand therapies, the likely increase in the number of generic drugs that will be available over the next few years as a result of the expiration of certain drug patents held by brand-name pharmaceutical manufacturers and the rate of conversion from brand products to those generic drugs, price increases and price deflation, general economic conditions in the United States, competition within the industry, customer consolidation, changes in pharmaceutical manufacturer pricing and distribution policies and practices, increased downward pressure on government and other third party reimbursement rates to our customers, and changes in Federal government rules and regulations.

#### Pharmaceutical Distribution Services Segment

The Pharmaceutical Distribution Services segment grew its revenue by 4.0% and 3.9% from the prior year quarter and six month period, respectively. Intrasegment revenue between ABDC and ABSG has been eliminated in the presentation of total Pharmaceutical Distribution Services revenue. Intrasegment revenue primarily consisted of ABSG sales directly to ABDC customer sites or ABSG sales to ABDC facilities. Intrasegment revenue was $2.2 billion and $1.8 billion in the quarters ended March 31, 2017 and 2016, respectively, and $4.4 billion and $3.5 billion in the six month periods ended March 31, 2017 and 2016, respectively.

ABDC’s revenue of $30.1 billion and $61.3 billion in the quarter and six months ended March 31, 2017 increased 3.6% from the prior year periods (before intrasegment eliminations). The increases in ABDC’s revenue were primarily due to the growth of some of ABDC's larger customers and due to overall market growth within the retail customer segment, offset in part by a decline in sales of products that treat Hepatitis C.

ABSG’s revenue of $7.6 billion and $15.1 billion in the quarter and six months ended March 31, 2017 increased 11.0% and 10.7%, respectively, from the prior year periods (before intrasegment eliminations). The increases in ABSG’s revenue were primarily due to strong overall performance, especially in the sale of oncology products, and increased sales in our third party logistics business.

A number of our contracts with customers, including GPOs, are typically subject to expiration each year. We may lose a significant customer if any existing contract with such customer expires without being extended, renewed, or replaced. During the six months ended March 31, 2017, no significant contracts expired. Our contract with Express Scripts was scheduled to expire in September 2017; however, in April 2017, we signed a new five-year agreement with Express Scripts that expires in September 2022. Over the next twelve months, there are no significant contracts scheduled to expire. Additionally, from time to time, other significant contracts may be renewed prior to their expiration dates. If those contracts are renewed at less favorable terms, they may also negatively impact our revenue, results of operations, and cash flows.

#### Other

Revenue in Other increased 6.0% and 5.7% from the prior year quarter and six month period, respectively, primarily due to increased revenue from MWI primarily due to strong growth in its companion animal business and ABCS due to its growth in manufacturer service programs.

### Gross Profit

*(dollars in thousands)*

|  | Three months ended March 31, 2017 | 2016 | Change | Six months ended March 31, 2017 | 2016 | Change |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Pharmaceutical Distribution Services | $868,847 | 882,209 | (1.5)% | 1,624,092 | 1,654,177 | (1.8)% |
| Other | 301,077 | 285,494 | 5.5% | 610,438 | 567,174 | 7.6% |
| Intersegment eliminations | (1) | — |  | (14) | — |  |
| Gain from antitrust litigation settlements | — | 7 |  | 1,395 | 12,798 |  |
| LIFO credit (expense) | 86,504 | (92,379) |  | 58,196 | (193,941) |  |
| Gross profit | $1,256,427 | $1,075,331 | 16.8% | $2,294,107 | $2,040,208 | 12.4% |

Gross profit increased 16.8%, or $181.1 million, and 12.4%, or $253.9 million, from the prior year quarter and six month period, respectively. The increases were primarily due to the $178.9 million and $252.1 million decrease in LIFO expense from the prior year quarter and six month period, respectively. Additionally, increases in gross profit in Other were offset by decreases in gross profit of Pharmaceutical Distribution Services. The LIFO credit in the current year quarter and six month period was primarily driven by lower expected brand inflation and greater generic deflation for fiscal 2017 in comparison to those expectations at March 31, 2016 for the prior fiscal year.

Our cost of goods sold for interim periods includes a LIFO provision that is based on our estimated annual LIFO provision. The annual LIFO provision, which we estimate on a quarterly basis, is affected by expected changes in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by market and other external influences, many of which are difficult to predict. The generic deflation rate used for estimating our LIFO provision is typically greater than our base generic deflation rate (currently at -7% to -9% for fiscal 2017) due to various factors, including but not limited to declining prices on new generic products and changes in generic volumes and/or mix of products. Changes to any of the above factors may have a material impact to our annual LIFO provision.

Pharmaceutical Distribution Services gross profit decreased 1.5%, or $13.4 million, and 1.8%, or $30.1 million, from the prior year quarter and six month period, respectively. Gross profit in the current year quarter was adversely impacted by prior year contract renewals in the second half of fiscal 2016 at less favorable terms with a significant GPO customer and Kaiser and a lower contribution from PharMEDium as it shipped fewer units while we increased our investment in quality control and quality assurance systems to enhance product quality and patient safety and to meet all of PharMEDium's commitments to the FDA pursuant to the new federal requirements for outsourcing facilities. We expect a lower contribution from PharMEDium in the second half of fiscal 2017 until the aforementioned procedures have been fully implemented. Gross profit in the current year six month period was adversely impacted by the above-mentioned contract renewals and lower price appreciation, offset in part by the incremental contribution from PharMEDium, which was acquired on November 6, 2015. As a percentage of revenue, Pharmaceutical Distribution Services gross profit margin of 2.45% and 2.25% in the quarter and six months ended March 31, 2017, respectively, decreased 13 basis points from the prior year periods primarily due to contract renewals at less favorable terms and increased sales to some of our larger customers that typically have a lower gross profit margin.

Gross profit in Other increased 5.5%, or $15.6 million, and 7.6%, or $43.3 million, from the prior year quarter and six month period, respectively. The increases from the prior year periods were primarily due to revenue growth of ABCS and MWI. As a percentage of revenue, gross profit margin in Other of 17.75% in the quarter ended March 31, 2017 decreased from 17.85% in the prior year quarter. As a percentage of revenue, gross profit margin in Other of 18.17% in the six months ended March 31, 2017 increased from 17.85% in the prior year six month period primarily due to improved gross profit margin at ABCS and MWI.

No significant gains from antitrust litigation settlements with pharmaceutical manufacturers were recognized in the quarters ended March 31, 2017 and 2016. We recognized gains of $1.4 million and $12.8 million from antitrust litigation settlements with pharmaceutical manufacturers during the six months ended March 31, 2017 and 2016, respectively. The gains were recorded as reductions to cost of goods sold.

### Operating Expenses

*(dollars in thousands)*

|  | Three months ended March 31, 2017 | 2016 (As Revised) | Change | Six months ended March 31, 2017 | 2016 (As Revised) | Change |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Distribution, selling, and administrative | $521,843 | $519,466 | 0.5% | $1,042,390 | $1,044,543 | (0.2)% |
| Depreciation and amortization | 97,669 | 92,836 | 5.2% | 193,749 | 175,798 | 10.2% |
| Warrants income | — | (503,946) |  | — | (36,571) |  |
| Employee severance, litigation, and other | 11,934 | 17,617 |  | 33,000 | 36,485 |  |
| Pension settlement charge | — | (1,124) |  | — | 47,607 |  |
| Total operating expenses | $631,446 | $124,849 | 405.8% | $1,269,139 | $1,267,862 | 0.1% |

Distribution, selling, and administrative expenses increased 0.5%, or $2.4 million, from the prior year quarter. Distribution, selling, and administrative expenses decreased 0.2%, or $2.2 million, from the prior year six month period. As a percentage of revenue, distribution, selling, and administrative expenses were 1.40% and 1.38% in the current year quarter and six month period, respectively, and represent a decrease of 6 basis points compared to the prior year periods. The decreases in expense as a percentage of revenue in comparison to the prior year periods were primarily due to initiatives taken in the second half of fiscal 2016 to improve operating efficiency across many of our businesses and certain administrative functions.

Depreciation expense increased 9.0% and 9.4% from the prior year quarter and six month period, respectively, due to an increase in the amount of capital projects being depreciated. Amortization expense increased 0.2% and 11.4% from the prior year quarter and prior year six month period, respectively. The increase in amortization expense from the prior year six month period was primarily due to the amortization of intangible assets originating from our November 6, 2015 acquisition of PharMEDium.

There was no Warrants income in the current fiscal year quarter as the Warrants were exercised in March 2016 and August 2016.

Employee severance, litigation, and other for the quarter ended March 31, 2017 included $7.6 million of costs primarily related to facility closures and certain acquisition-related integration costs, and $4.3 million of deal-related transaction costs. Employee severance, litigation, and other for the six months ended March 31, 2017 included a $16.0 million settlement of a state litigation proceeding (see Note 8 of the Notes to the Consolidated Financial Statements for further details), $12.2 million of costs primarily related to facility closures and certain acquisition-related integration costs, and $4.8 million of deal-related transaction costs. Employee severance, litigation, and other for the quarter ended March 31, 2016 included $13.0 million of costs related to customer contract extensions (primarily related to the settlement of certain disputed items), $2.6 million of employee severance and other costs, and $2.0 million of deal-related transaction costs. Employee severance, litigation, and other for the six months ended March 31, 2016 included $18.1 million of deal-related transaction costs (primarily related to professional fees with respect to the PharMEDium acquisition), $13.0 million of cost related to customer contract extensions, and $5.4 million of employee severance and other costs.

### Operating Income

*(dollars in thousands)*

|  | Three months ended March 31, 2017 | 2016 (As Revised) | Change | Six months ended March 31, 2017 | 2016 (As Revised) | Change |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Pharmaceutical Distribution Services | $482,265 | $500,165 | (3.6)% | $856,267 | $881,419 | (2.9)% |
| Other | 106,206 | 93,956 | 13.0% | 218,412 | 189,521 | 15.2% |
| Intersegment eliminations | (1) | — |  | (14) | — |  |
| Total segment operating income | 588,470 | 594,121 | (1.0)% | 1,074,665 | 1,070,940 | 0.3% |
| Gain from antitrust litigation settlements | — | 7 |  | 1,395 | 12,798 |  |
| LIFO credit (expense) | 86,504 | (92,379) |  | 58,196 | (193,941) |  |
| Acquisition-related intangibles amortization | (38,059) | (38,720) |  | (76,288) | (69,930) |  |
| Warrants income | — | 503,946 |  | — | 36,571 |  |
| Employee severance, litigation, and other | (11,934) | (17,617) |  | (33,000) | (36,485) |  |
| Pension settlement | — | 1,124 |  | — | (47,607) |  |
| Operating income | $624,981 | $950,482 |  | $1,024,968 | $772,346 |  |

Segment operating income is evaluated before gain from antitrust litigation settlements; LIFO credit (expense); acquisition-related intangibles amortization; Warrants income; employee severance, litigation, and other; and pension settlement.

Pharmaceutical Distribution Services operating income decreased 3.6%, or $17.9 million, and 2.9%, or $25.2 million, from the prior year quarter and six month period, respectively, primarily due to the decrease in gross profit. As a percentage of revenue, Pharmaceutical Distribution Services operating income margin decreased 10 basis points and 8 basis points from the prior year quarter and six month period, respectively, primarily due to the prior year contract renewals at less favorable terms and increased sales to some of our larger customers that typically have a lower gross profit margin, offset in part by our initiatives to improve operating efficiency.

Operating income in Other increased 13.0%, or $12.3 million, and 15.2%, or $28.9 million, from the prior year quarter and six month period, respectively, primarily due to the gross profit increases of ABCS and MWI, offset in part by an increase in operating expenses.

Interest expense, net and the respective weighted average interest rates in the quarters ended March 31, 2017 and 2016 were as follows:

*(dollars in thousands)*

|  | 2017 Amount | Weighted Average Interest Rate | 2016 Amount (As Revised) | Weighted Average Interest Rate |
| --- | ---: | ---: | ---: | ---: |
| Interest expense | $37,885 | 2.84% | $36,712 | 2.67% |
| Interest income | (586) | 0.41% | (746) | 0.80% |
| Interest expense, net | $37,299 |  | $35,966 |  |

25

Interest expense, net and the respective weighted average interest rates in the six months ended March 31, 2017 and 2016 were as follows:

*(dollars in thousands)*

|  | 2017 Amount | Weighted Average Interest Rate | 2016 Amount (As Revised) | Weighted Average Interest Rate |
| --- | ---: | ---: | ---: | ---: |
| Interest expense | $75,872 | 2.83% | $71,161 | 2.71% |
| Interest income | (1,601) | 0.40% | (1,454) | 0.42% |
| Interest expense, net | $74,271 |  | $69,707 |  |

Interest expense, net increased 3.7%, or $1.3 million, from the prior year quarter and 6.5%, or $4.6 million, from the prior year six month period. The increase in interest expense, net from the prior year quarter and six month period was primarily due to an increase in our financing obligations related to leased construction assets.

Our effective tax rates were 30.6% and 31.1% in the three and six months ended March 31, 2017, respectively. Our effective tax rates were 34.1% and (32.6)% in the three and six months ended March 31, 2016, respectively. Our effective income tax rates in the three and six months ended March 31, 2017 were favorably impacted due to growth of our international businesses and also benefited from stock option exercises and restricted stock vesting. Prior to fiscal 2017, tax benefits resulting from share-based compensation were recorded as adjustments to Additional Paid-In Capital within Stockholders' Equity. Our effective tax rate in the six months ended March 31, 2016 benefited from the receipt of an IRS private letter ruling that entitled us to an income tax deduction equal to the fair value of the Warrants on the dates of exercise.

Net income was $411.5 million and $658.7 million in the quarter and six months ended March 31, 2017, respectively, as compared to net income of $603.5 million and $933.1 million in the prior year quarter and six months ended March 31, 2016, respectively. Net income was higher in the prior year quarter primarily due to Warrants income, offset in part by a decrease in LIFO expense. Net income was higher in the prior year six month period primarily due to the large income tax benefit, as described above, offset in part by a decrease in LIFO expense.

### Liquidity and Capital Resources

The following table illustrates our debt structure at March 31, 2017, including availability under the multi-currency revolving credit facility, the receivables securitization facility, the revolving credit note, and the overdraft facility:

*(in thousands)*

| Fixed-Rate Debt: | Outstanding Balance | Additional Availability |
| --- | ---: | ---: |
| $600,000, 1.15% senior notes due 2017 | $599,794 | $— |
| $400,000, 4.875% senior notes due 2019 | 398,034 | — |
| $500,000, 3.50% senior notes due 2021 | 497,619 | — |
| $500,000, 3.40% senior notes due 2024 | 496,521 | — |
| $500,000, 3.25% senior notes due 2025 | 494,608 | — |
| $500,000, 4.25% senior notes due 2045 | 493,974 | — |
| Total fixed-rate debt | 2,980,550 | — |
| **Variable-Rate Debt:** |  |  |
| Revolving credit note | — | 75,000 |
| Receivables securitization facility due 2019 | 500,000 | 950,000 |
| Term loans due 2020 | 597,458 | — |
| Multi-currency revolving credit facility due 2021 | — | 1,400,000 |
| Overdraft facility due 2021 (£30,000) | 16,053 | 21,603 |
| Total variable-rate debt | 1,113,511 | 2,446,603 |
| Total debt | $4,094,061 | $2,446,603 |

Our operating results have generated cash flows, which, together with availability under our debt agreements and credit terms from suppliers, have provided sufficient capital resources to finance working capital and cash operating requirements, and to fund capital expenditures, acquisitions, repayment of debt, the payment of interest on outstanding debt, dividends, and repurchases of shares of our common stock.

Our primary ongoing cash requirements will be to finance working capital, fund the repayment of debt, fund the payment of interest on debt, fund repurchases of our common stock, fund the payment of dividends, finance acquisitions, and fund capital expenditures and routine growth and expansion through new business opportunities. Future cash flows from operations and borrowings are expected to be sufficient to fund our ongoing cash requirements.

As of March 31, 2017 and September 30, 2016, our cash and cash equivalents held by foreign subsidiaries were $715.3 million and $582.9 million, respectively. We expect that our cash and cash equivalents held by foreign subsidiaries will grow, but it is generally based in U.S. dollar denominated holdings. Amounts held by foreign subsidiaries are generally subject to U.S. income taxation on repatriation to the U.S. We do not have any plans to repatriate these amounts to the U.S., as our foreign subsidiaries intend to indefinitely reinvest this cash in foreign investments or foreign operations.

We have increased seasonal needs related to our inventory build during the December and March quarters that, depending on our cash balance, can require the use of our credit facilities to fund short-term capital needs. The largest amount of intra-period borrowings under our revolving and securitization credit facilities that was outstanding at any one time during the six months ended March 31, 2017 was $626.1 million. We had $6,706.0 million of cumulative intra-period borrowings that were repaid under our credit facilities during the six months ended March 31, 2017.

We have a $1.4 billion multi-currency senior unsecured revolving credit facility ("Multi-Currency Revolving Credit Facility"), which expires in November 2021, with a syndicate of lenders. Interest on borrowings under the Multi-Currency Revolving Credit Facility accrues at specified rates based on our debt rating and ranges from 70 basis points to 110 basis points over CDOR/LIBOR/EURIBOR/Bankers Acceptance Stamping Fee, as applicable (91 basis points over CDOR/LIBOR/EURIBOR/Bankers Acceptance Stamping Fee at March 31, 2017) and from 0 basis points to 10 basis points over the alternate base rate and Canadian prime rate, as applicable. We pay facility fees to maintain the availability under the Multi-Currency Revolving Credit Facility at specified rates based on our debt rating, ranging from 5 basis points to 15 basis points, annually, of the total commitment (9 basis points at March 31, 2017). We may choose to repay or reduce our commitments under the Multi-Currency Revolving Credit Facility at any time. The Multi-Currency Revolving Credit Facility contains covenants, including compliance with a financial leverage ratio test, as well as others that impose limitations on, among other things, indebtedness of subsidiaries and asset sales, with which we were compliant as of March 31, 2017.

We have a commercial paper program whereby we may from time to time issue short-term promissory notes in an aggregate amount of up to $1.4 billion at any one time. Amounts available under the program may be borrowed, repaid, and re-borrowed from time to time. The maturities on the notes will vary, but may not exceed 365 days from the date of issuance. The notes will bear interest, if interest bearing, or will be sold at a discount from their face amounts. The commercial paper program does not increase our borrowing capacity as it is fully backed by our Multi-Currency Revolving Credit Facility. There were no borrowings outstanding under our commercial paper program as of March 31, 2017.

We have a $1,450 million receivables securitization facility ("Receivables Securitization Facility"), which expires in November 2019. We have available to us an accordion feature whereby the commitment on the Receivables Securitization Facility may be increased by up to $250 million, subject to lender approval, for seasonal needs during the December and March quarters. Interest rates are based on prevailing market rates for short-term commercial paper or LIBOR plus a program fee. We pay a customary unused fee at prevailing market rates, annually, to maintain the availability under the Receivables Securitization Facility. The Receivables Securitization Facility contains similar covenants to the Multi-Currency Revolving Credit Facility, with which we were compliant as of March 31, 2017.

We have an uncommitted, unsecured line of credit available to us pursuant to a revolving credit note ("Revolving Credit Note"). The Revolving Credit Note provides us with the ability to request short-term unsecured revolving credit loans from time to time in a principal amount not to exceed $75 million. The Revolving Credit Note may be decreased or terminated by the bank or us at any time without prior notice. We also have a £30 million uncommitted U.K. overdraft facility ("Overdraft Facility"), which expires in February 2021, to fund short term normal trading cycle fluctuations related to our MWI business.

In February 2015, we entered into a $1.0 billion variable-rate term loan ("February 2015 Term Loan"), which matures in 2020. Through March 31, 2017, we elected to make principal payments, prior to the scheduled repayment dates, of $725 million on the February 2015 Term Loan, and as a result, our next required principal payment is due upon maturity. The February 2015 Term Loan bears interest at a rate equal either to a base rate plus a margin, or LIBOR, plus a margin. The margin is based on our public debt ratings and ranges from 75 basis points to 125 basis points over LIBOR (100 basis points at March 31, 2017) and 0 basis points to 25 basis points over a base rate. The February 2015 Term Loan contains similar covenants to the Multi-Currency Revolving Credit Facility, with which we were compliant as of March 31, 2017.

In November 2015, we entered into a $1.0 billion variable-rate term loan (the "November 2015 Term Loan"), which matures in 2020. Through March 31, 2017, we elected to make principal payments, prior to the scheduled repayment dates, of $650 million on the November 2015 Term Loan, and as a result, our next scheduled principal payment is due upon maturity. The November 2015 Term Loan bears interest at a rate equal either to a base rate, plus a margin, or LIBOR, plus a margin. The margin is based on our public debt ratings and ranges from 75 basis points to 125 basis points over LIBOR (100 basis points at March 31, 2017) and 0 basis points to 25 basis points over a base rate. The November 2015 Term Loan contains similar covenants to the Multi-Currency Revolving Credit Facility, with which we were compliant as of March 31, 2017.

In May 2016, our board of directors authorized a share repurchase program that, together with availability remaining under the previously approved August 2013 share repurchase program, permitted us to purchase up to $750 million in shares of our common stock, subject to market conditions. During the three months ended December 31, 2016, we purchased $118.8 million to complete our authorization under this program.

In November 2016, our board of directors authorized a new share repurchase program allowing us to purchase up to $1.0 billion in shares of our common stock, subject to market conditions. During the six months ended March 31, 2017, we purchased $111.1 million of our common stock under this program. As of March 31, 2017, we had $888.9 million of availability remaining under the November 2016 share repurchase program.

We have market risk exposure to interest rate fluctuations relating to our debt. We manage interest rate risk by using a combination of fixed-rate and variable-rate debt. The amount of variable-rate debt fluctuates during the year based on our working capital requirements. We periodically evaluate financial instruments to manage our exposure to fixed and variable interest rates. However, there are no assurances that such instruments will be available in the combinations we want and/or on terms acceptable to us. There were no such financial instruments in effect at March 31, 2017.

We also have market risk exposure to interest rate fluctuations relating to our cash and cash equivalents. We had $2,404.4 million in cash and cash equivalents at March 31, 2017. The unfavorable impact of a hypothetical decrease in interest rates on cash and cash equivalents would be partially offset by the favorable impact of such a decrease on variable-rate debt. For every $100 million of cash invested that is in excess of variable-rate debt, a 10 basis point decrease in interest rates would increase our annual net interest expense by $0.1 million.

We have minimal exposure to foreign currency and exchange rate risk from our non-U.S. operations. Our largest exposure to foreign exchange rates exists primarily with the Euro, the U.K. Pound Sterling, the Canadian Dollar, and the Brazilian Real. Revenue from our foreign operations is less than one percent of our consolidated revenue. We may utilize foreign currency denominated forward contracts to hedge against changes in foreign exchange rates. We may use derivative instruments to hedge our foreign currency exposure, but not for speculative or trading purposes. As of March 31, 2017, we had one foreign currency denominated contract outstanding that hedges the foreign currency exchange risk of a C$32.5 million outstanding note.

Following is a summary of our contractual obligations for future principal and interest payments on our debt, minimum rental payments on our noncancelable operating leases and financing obligations, and minimum payments on our other commitments at March 31, 2017:

| Payments Due by Period (in thousands) | Debt, Including Interest Payments | Operating Leases | Financing Obligations 1 | Other Commitments | Total |
| --- | ---: | ---: | ---: | ---: | ---: |
| Within 1 year | $731,634 | $61,464 | $26,218 | $118,946 | $938,262 |
| 1-3 years | 1,399,262 | 97,657 | 59,967 | 45,060 | 1,601,946 |
| 4-5 years | 975,175 | 64,216 | 58,214 | 13,384 | 1,110,989 |
| After 5 years | 2,080,000 | 64,099 | 167,383 | — | 2,311,482 |
| Total | $5,186,071 | $287,436 | $311,782 | $177,390 | $5,962,679 |
| 1 Represents the portion of future minimum lease payments relating to facility leases where we were determined to be the accounting owner (see Note 1 of the Notes to Consolidated Financial Statements in our Annual Report on Form 10-K for the fiscal year ended September 30, 2016 for a more detailed description of our accounting for leases). These payments are recognized as reductions to the financing obligation and as interest expense and exclude the future non-cash termination of the financing obligation. |  |  |  |  |  |

We outsource to IBM Global Services a significant portion of our corporate and ABDC data center operations. The remaining commitment under our arrangement, which expires in January 2021, is approximately $90.2 million as of March 31, 2017, of which $43.2 million represents our commitment over the next twelve months, and is included in "Other commitments" in the above table.

We have commitments to purchase non-returnable product from pharmaceutical manufacturers. We are required to purchase product at prices that we believe will represent market prices. We currently estimate that our remaining purchase commitment under these agreements is approximately $66.2 million as of March 31, 2017, all of which represents our commitment over the next twelve months, and is included in "Other commitments" in the above table.

Our liability for uncertain tax positions was $99.2 million (including interest and penalties) as of March 31, 2017. This liability represents an estimate of tax positions that we have taken in our tax returns which may ultimately not be sustained upon examination by taxing authorities. Since the amount and timing of any future cash settlements cannot be predicted with reasonable certainty, the estimated liability has been excluded from the above contractual obligations table.

During the six months ended March 31, 2017, our operating activities provided $368.4 million of cash in comparison to cash provided of $1,632.0 million in the prior year period. Cash provided by operations during the six months ended March 31, 2017 was principally the result of net income of $658.7 million, non-cash items of $353.4 million, and an increase in accounts payable of $351.0 million, offset, in part, by an increase in merchandise inventories of $556.1 million and an increase in accounts receivable of $417.7 million. The non-cash items were comprised primarily of $159.4 million of deferred income tax expense,$127.2 million of depreciation expense, and $85.2 million of amortization expense. The increase in accounts payable was primarily driven by the increase in merchandise inventories and the timing of payments to our suppliers. We increased our merchandise inventories at March 31, 2017 to support the increase in business volume and, consistent with prior years, due to seasonal needs. The increase in accounts receivable was the result of our revenue growth and a gradual change in payment terms with our largest customer that began in May 2016 as part of a contract amendment that, among other things, extended the term of our relationship with the customer.

We use days sales outstanding, days inventory on hand, and days payable outstanding to evaluate our working capital performance. The below financial metrics are calculated based upon a quarterly average and can be impacted by the timing of cash receipts and disbursements, which can vary significantly depending upon the day of the week in which the month ends.

|  | Three months ended March 31, 2017 | 2016 | Six months ended March 31, 2017 | 2016 |
| --- | ---: | ---: | ---: | ---: |
| Days sales outstanding | 23.6 | 21.7 | 23.1 | 21.3 |
| Days inventory on hand | 30.3 | 31.2 | 30.3 | 30.3 |
| Days payable outstanding | 56.4 | 57.3 | 56.4 | 56.2 |

The increase in days sales outstanding from the prior year periods was the result of a gradual change in payment terms with our largest customer that began in May 2016 and ended in February 2017. We currently expect cash flows from operating activities in fiscal 2017 to be between $1.6 billion and $1.9 billion.

Our cash flows from operating activities can vary significantly from period to period based on fluctuations in our period end working capital. Additionally, any changes to payment terms with a significant customer or manufacturer supplier could have a material impact to our cash flows from operations. Operating cash flows during the six months ended March 31, 2017 included $62.1 million of interest payments and $32.5 million of income tax payments, net of refunds. Operating cash flows during the six months ended March 31, 2016 included $58.9 million of interest payments and $6.9 million of income tax refunds, net of payments.

During the six months ended March 31, 2016, our operating activities provided $1,632.0 million of cash. Cash provided by operations during the six months ended March 31, 2016 was principally the result of net income of $933.1 million and an increase in accounts payable of $2,070.7 million, offset, in part, by an increase in merchandise inventories of $1,047.0 million and an increase in accounts receivable of $472.1 million. The increase in accounts payable was primarily driven by the increase in merchandise inventories and the timing of payments to our suppliers. We increased our merchandise inventories at March 31, 2016 to support the increase in business volume and due to seasonal needs. Accounts receivable increased as a result of our increased revenue volume, including additional sales to WBA.

Capital expenditures for the six months ended March 31, 2017 and 2016 were $262.7 million and $180.0 million, respectively. Significant capital expenditures in the six months ended March 31, 2017 included costs associated with expanding distribution capacity and technology initiatives, including costs related to enhancing and upgrading our enterprise resource planning systems. We currently expect to invest approximately $500 million for capital expenditures during fiscal 2017. Significant capital expenditures in the six months ended March 31, 2016 included technology initiatives, including costs related to the development of track-and-trace technology, costs associated with expanding distribution capacity, and expansion of support facilities.

Cost of acquired companies, net of cash acquired, in the six months ended March 31, 2016 was $2,731.4 million and primarily consisted of our PharMEDium acquisition.

Net cash used in financing activities in the six months ended March 31, 2017 principally included $229.9 million in purchases of our common stock and $160.1 million in cash dividends paid on our common stock. Net cash provided by financing activities in the six months ended March 31, 2016 principally included $1.2 billion received upon the exercises of the 2016 Warrants by WBA and $1.0 billion of borrowings under our November 2015 Term Loan, offset, in part, by $436.8 million in purchases of our common stock.

In November 2016, our board of directors increased the quarterly cash dividend by 7% from $0.340 per share to $0.365 per share. We anticipate that we will continue to pay quarterly cash dividends in the future. However, the payment and amount of future dividends remains within the discretion of our board of directors and will depend upon our future earnings, financial condition, capital requirements, and other factors.

### Cautionary Note Regarding Forward-Looking Statements

Certain of the statements contained in this Management's Discussion and Analysis of Financial Condition and Results of Operations and elsewhere in this report are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Words such as "expect," "likely," "outlook," "forecast," "would," "could," "should," "can," "will," "project," "intend," "plan," "continue," "sustain," "synergy," "on track," "believe," "seek," "estimate," "anticipate," "may," "possible," "assume," variations of such words, and similar expressions are intended to identify such forward-looking statements. These statements are based on management's current expectations and are subject to uncertainty and change in circumstances. These statements are not guarantees of future performance and are based on assumptions that could prove incorrect or could cause actual results to vary materially from those indicated. Among the factors that could cause actual results to differ materially from those projected, anticipated, or implied are the following: unfavorable trends in brand and generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation; competition and industry consolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our products and services; changes in pharmaceutical market growth rates; substantial defaults in payment, material reduction in purchases by or the loss, bankruptcy or insolvency of a major customer; changes to the customer or supplier mix; the retention of key customer or supplier relationships under less favorable economics or the adverse resolution of any contract or other dispute with customers or suppliers; changes to customer or supplier payment terms; the disruption of AmerisourceBergen's cash flow and ability to return value to its stockholders in accordance with its past practices; risks associated with the strategic, long-term relationship between Walgreens Boots Alliance, Inc. and AmerisourceBergen, including with respect to the pharmaceutical distribution agreement and/or the global sourcing arrangement; changes in the United States healthcare and regulatory environment, including changes that could impact prescription drug reimbursement under Medicare and Medicaid; increasing governmental regulations regarding the pharmaceutical supply channel and pharmaceutical compounding; federal and state government enforcement initiatives to detect and prevent suspicious orders of controlled substances and the diversion of controlled substances; federal and state prosecution of alleged violations of related laws and regulations, and any related litigation, including shareholder derivative lawsuits or other disputes relating to our distribution of controlled substances; increased federal scrutiny and qui tam litigation for alleged violations of fraud and abuse laws and regulations and/or any other laws and regulations governing the marketing, sale, purchase and/or dispensing of pharmaceutical products or services and any related litigation; material adverse resolution of pending legal proceedings; declining reimbursement rates for pharmaceuticals; the acquisition of businesses that do not perform as expected, or that are difficult to integrate or control, including the integration of PharMEDium, or the inability to capture all of the anticipated synergies related thereto; regulatory action in connection with the production, labeling or packaging of products compounded by our compounded sterile preparations (CSP) business; declining economic conditions in the United States and abroad; financial market volatility and disruption; the loss, bankruptcy or insolvency of a major supplier; interest rate and foreign currency exchange rate fluctuations; managing foreign expansion, including non-compliance with the U.S. Foreign Corrupt Practices Act, anti-bribery laws and economic sanctions and import laws and regulations; malfunction, failure or breach of sophisticated information systems to operate as designed; risks generally associated with data privacy regulation and the international transfer of personal data; changes in tax laws or legislative initiatives that could adversely affect AmerisourceBergen's tax positions and/or AmerisourceBergen's tax liabilities or adverse resolution of challenges to AmerisourceBergen's tax positions; natural disasters or other unexpected events that affect AmerisourceBergen's operations; the impairment of goodwill or other intangible assets, resulting in a charge to earnings; and other economic, business, competitive, legal, tax, regulatory and/or operational factors affecting AmerisourceBergen's business generally. Certain additional factors that management believes could cause actual outcomes and results to differ materially from those described in forward-looking statements are set forth (i) elsewhere in this report, (ii) in Item 1A (Risk Factors), in the Company’s Annual Report on Form 10-K for the fiscal year ended September 30, 2016 and elsewhere in that report and (iii) in other reports filed by the Company pursuant to the Securities Exchange Act.

## Market risk

As filed, 262 characters.

The Company’s most significant market risks are the effects of changing interest rates, foreign currency risk, and changes in the price and volatility of the Company’s common stock. See the discussion under "Liquidity and Capital Resources" in Item 2 on page 26.

## Controls and procedures

As filed, 1,360 characters.

### Evaluation of Disclosure Controls and Procedures

The Company maintains disclosure controls and procedures that are intended to ensure that information required to be disclosed in the Company’s reports submitted under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC. These controls and procedures also are intended to ensure that information required to be disclosed in such reports is accumulated and communicated to management to allow timely decisions regarding required disclosures.

The Company’s Chief Executive Officer and Chief Financial Officer, with the participation of other members of the Company’s management, have evaluated the effectiveness of the Company’s disclosure controls and procedures (as such term is defined in Rules 13a — 15(e) and 15d — 15(e) under the Exchange Act) and have concluded that the Company’s disclosure controls and procedures were effective for their intended purposes as of the end of the period covered by this report.

### Changes in Internal Control over Financial Reporting

During the second quarter of fiscal 2017, there was no change in AmerisourceBergen Corporation’s internal control over financial reporting that materially affected, or is reasonably likely to materially affect, internal control over financial reporting.

## Risk factors

As filed, 141 characters.

Our significant business risks are described in Item 1A to Form 10-K for the year ended September 30, 2016 to which reference is made herein.

Filed May 4, 2017.
Source: SEC EDGAR, the filing index for accession 0001140859-17-000020. Last ingested by Listed: Nov 15, 2026, 01:23 ET. No prices; not investment advice.
